Tpg Gp A, LLC Vaxcyte, Inc. Transaction History

Tpg Gp A, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$20.58 - $47.95 $43.1 Million - $100 Million	-2,095,168 Reduced 63.77%	1,190,336 $57.1 Million
Q3 2022 Nov 14, 2022	SELL	$21.69 - $28.53 $8.28 Million - $10.9 Million	-381,921 Reduced 10.41%	3,285,504 $78.9 Million
Q2 2022 Sep 02, 2022	SELL	$17.68 - $26.58 $396,191 - $595,631	-22,409 Reduced 0.61%	3,667,425 $79.8 Million
Q2 2022 Aug 15, 2022	SELL	$17.68 - $26.58 $6.46 Million - $9.71 Million	-365,258 Reduced 9.01%	3,689,834 $80.3 Million
Q1 2022 May 16, 2022	SELL	$17.46 - $26.36 $2.66 Million - $4.02 Million	-152,483 Reduced 3.62%	4,055,092 $97.9 Million
Q4 2021 Feb 14, 2022	BUY	$19.32 - $26.45 $81.3 Million - $111 Million	4,207,575 New	4,207,575 $100 Million

357

123M

775K

433K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.26B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Tpg Gp A, LLC, based on Form 13F filings with the SEC.

Stay updated on Tpg Gp A, LLC with notifications on news.